Conv. Plasma
Nigella Sativa

All probiotics studies
Meta analysis
study COVID-19 treatment researchProbioticsProbiotics (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 80% Improvement Relative Risk Recovery 18% Recovery time 8% no CI Probiotics  Hassan et al.  EARLY TREATMENT  RCT Is early treatment with probiotics beneficial for COVID-19? RCT 100 patients in Egypt (July 2021 - August 2022) Lower hospitalization (p=0.2) and improved recovery (p=0.42), not sig. Hassan et al., Research Square, June 2023 Favors probiotics Favors control

The effects of probiotic Lactobacillus acidophilus and colchicine on the control of symptoms, duration, and disease progression of mild and moderate cases of COVID-19: A randomized controlled clinical trial

Hassan et al., Research Square, doi:10.21203/
Jun 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 150 patients in Egypt showing no significant difference in outcomes with probiotic lactobacillus acidophilus, although hospitalization was 2% versus 10% for control. SOC included vitamin C, D, and zinc.
The immune effects of probiotics are strain-specific.
This study includes colchicine and probiotics.
risk of hospitalization, 80.0% lower, RR 0.20, p = 0.20, treatment 1 of 50 (2.0%), control 5 of 50 (10.0%), NNT 12.
risk of no recovery, 17.9% lower, RR 0.82, p = 0.42, treatment 23 of 50 (46.0%), control 28 of 50 (56.0%), NNT 10.0.
recovery time, 8.3% lower, relative time 0.92, treatment 50, control 50.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hassan et al., 13 Jun 2023, Randomized Controlled Trial, Egypt, preprint, 6 authors, study period July 2021 - August 2022.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperProbioticsAll
The effects of probiotic Lactobacillus acidophilus and colchicine on the control of symptoms, duration, and disease progression of mild and moderate cases of COVID-19: A randomized controlled clinical trial
Samar Osama Ahmed Hassan, Ahmed Nour El-Din Hassan, Manal Sabry Mohamed, Mohamed Nabil Badawy Al Ashram, Mina Michael Nesim, Mohamed Farouk Allam
Background Coronavirus disease 2019 (COVID-19) is a newly emerging human disease caused by a novel coronavirus, causing a global pandemic crisis. Probiotics and/or colchicine may be considered as options for treatment since they have anti-viral, anti-in ammatory, and immunomodulatory effects. Objective To assess the effectiveness of probiotic supplements (Lactobacillus acidophilus) and colchicine on symptoms, duration, and progression of mild and moderate cases of COVID-19 infection. Methods A three-arm randomized controlled clinical trial was carried out in the triage clinic of the family medicine department at Ain Shams University Hospitals on 150 participants who had been diagnosed as COVID-19 patients with mild and moderate severity. Patients aged below 18 years or above 65 years with any comorbidities, pregnant or lactating females, and severe COVID-19 con rmed cases were excluded. Randomization was done by using sealed envelopes containing codes for intervention or control. Patients are followed up for improvement of their symptoms with no development of new symptoms over the course of two weeks. Results A total of 150 patients with mild and moderate severity of COVID-19 were enrolled in the study, 50 patients in each arm; around one third (34.7%) of the participants were aged between 29 and 39 years; one-quarter (24.7%) were aged between 18 and 28 years and 40.6% were aged 40 years and above. The mean duration of symptoms improvement was 12, 11 and 12 in the colchicine, probiotic, and control groups, respectively. Improvement of in ammatory markers over time occurred in each of the three groups, with no statistically signi cant difference between them. Conclusion Probiotic Lactobacillus acidophilus and colchicine shows no signi cant effect on the symptoms, duration, and progression of mild and moderate cases of COVID-19.
Declarations Author contributions: Each author declares having participated in the activities. Funding: None. Figure 1 See image above for gure legend.
Abdelfattah, Korra, Ahmed, Use of colchicine in COVID-19 hospitalized patients, Egypt J Chest Dis Tuberc, doi:10.4103/ecdt.ecdt_59_21
Angurana, Coronavirus disease 2019: think about the link, Br J Nutr, doi:10.1017/S000711452000361X
Darbandi, Asadi, Ghanavati, Emamie, The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010-20, Int J Infect Dis, doi:10.1016/j.ijid.2021.02.011
Deftereos, Giannopoulos, Vrachatis, Siasos, Sg, Effect of vs Standard Care on Cardiac and In ammatory Biomarkers and Clinical Outcomes in Patients Hospitalized with Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.13136
Doerre, The uence of gender on COVID-19 infections and mortality in Germany: Insights from age-and gender-speci c modeling of contact rates, infections, and deaths in the early phase of the pandemic, PLoS One, doi:10.1371/journal.pone.0268119
Dorward, Yu, Hayward, Saville, Gbinigie et al., Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial, Br J Gen Pract, doi:10.3399/BJGP.2022.0083
Effenberger, Grabherr, Mayr, Schwaerzler, Nairz et al., Faecal calprotectin indicates intestinal in ammation in COVID-19, Gut, doi:10.1136/gutjnl-2020-321388
Farsalinos, Bagos, Giannouchos, Niaura, Barbouni et al., Smoking prevalence among hospitalized COVID-19 patients and its association with disease severity and mortality: an expanded reanalysis of a recent publication, Harm Reduct J, doi:10.1186/s12954-020-00437-5
Gorial, Maulood, Abdulamir, Alnuaimi, Bonyan, Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus Disease-19 infection, Ann Med Surg, doi:10.1016/j.amsu.2022.103593
Hakki, Zhou, Jonnerby, Singanayagam, Barnett et al., Onset and of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study, Lancet Respir Med, doi:10.1016/S2213-2600(22)00226-0
Hariyanto, Halim, Jodhinata, Yanto, Kurniawan, Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis, Clin Exp Pharmacol Physiol, doi:10.1111/1440-1681.13488
Hill, Guarner, Reid, Gibson, Merenstein et al., Expert consensus document. The International Scienti c Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic, Nat Rev Gastroenterol Hepatol, doi:10.1038/nrgastro.2014.66
Karatza, Ismailos, Karalis Colchicine for the treatment of COVID-19 patients: e cacy, safety, and model informed dosage regimens, Xenobiotica, doi:10.1080/00498254.2021
Leung, Hui, Kraus, Colchicine-Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum, doi:10.1016/j.semarthrit.2015.06.013
Lopes, Bonjorno, Giannini, Amaral, Menezes et al., Bene cial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open, doi:10.1136/rmdopen-2020-001455
Qin, Zhou, Hu, Zhang, Yang et al., Dysregulation of Immune Response in Patients with, Clin Infect Dis, doi:10.1093/cid/ciaa248
Sandhu, Tieng, Chilimuri, Franchin, Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection, Can J Infect Dis Med Microbiol, doi:10.1155/2020/8865954
Sarwar, Ali, Fatima, Sarfraz, Sarfraz et al., COVID-19, and hematological parameters: A meta-analysis, J Clin Lab Anal, doi:10.1002/jcla.24057
Siemieniuk, Bartoszko, Zeraatkar, Qasim, Martinez, Drug treatments for covid-19: living systematic review and network meta-analysis, BMJ, doi:10.1136/bmj.m2980
Soraya, Ulhaq, Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis, Med Clin (Barc), doi:10.1016/j.medcli.2020.05.017
Tardif, Bouabdallaoui, Allier, Gaudet, Shah et al., Colchicine for communitytreated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebocontrolled, multicentre trial, Lancet Respir Med, doi:10.1016/S2213-2600
Teranaka, Pan, Discharge criteria for patients with COVID-19 to long-term care facilities requires modi cation, Clin Med, doi:10.7861/clinmed.Let.21.1.2
Terkeltaub, Furst, Bennett, Kook, Crockett et al., High versus low dosing of oral colchicine for early acute gout are: Twenty-four-hour outcome of the rst multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study, Arthritis Rheum, doi:10.1002/art.27327
Wischmeyer, Tang, Ren, Bohannon, Ramirez et al., Daily Lactobacillus probiotic versus placebo in household contacts (PROTECT-EHC): a randomized clinical trial, MedRxiv, doi:10.1101/2022.01.04.21268275
Yasmin, Najeeb, Moeed, Hassan, Asghar, Safety and e cacy of in COVID-19 patients: A systematic review and meta-analysis of randomized control trials, PLoS One, doi:10.1371/journal.pone.0266245
Yeo Kaushal, Yeo, Enteric involvement of coronaviruses: Is faecal-oral transmission of SARS-CoV-2 possible?, Lancet Gastroenterol Hepatol, doi:10.1016/S2468-1253(20)30048-0
Zhang, Yeh, Ding, Liu, Zhang et al., Prospective study of probiotic supplementation results in immune stimulation and improvement of upper respiratory infection rate, Synth Syst Biotechnol, doi:10.1016/j.synbio.2018.03.001
Zuo, Zhang, Lui, Yeoh, Li et al., Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization, Gastroenterology, doi:10.1053/j.gastro.2020.05.048
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop